NASDAQ: IMVTImmunovant Inc Stock
$33.61+0.17 (+0.51%)
Updated Jun 16, 2026
IMVT Price
$33.61
Fair Value Price
$4.94
Market Cap
$6.90B
52 Week Low
$14.32
52 Week High
$36.28
P/E
-12.13x
P/B
8.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$505.61M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$407M
Beta
1.14
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
IMVT Overview
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMVT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IMVT
Ranked#392 of 462
Ranked#392 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important IMVT news, forecast changes, insider trades & much more!
IMVT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMVT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMVT ($33.61) is overvalued by 579.7% relative to our estimate of its Fair Value price of $4.94 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMVT ($33.61) is not significantly undervalued (579.7%) relative to our estimate of its Fair Value price of $4.94 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMVT due diligence checks available for Premium users.
Valuation
IMVT fair value
Fair Value of IMVT stock based on Discounted Cash Flow (DCF)
Price
$33.61
Fair Value
$4.94
Overvalued by
579.70%
IMVT ($33.61) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMVT ($33.61) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMVT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.13x
Industry
16.03x
Market
13.25x
IMVT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.09x
Industry
4.86x
IMVT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMVT's financial health
Profit margin
Revenue
$0.0
Net Income
-$147.9M
Profit Margin
0%
IMVT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$957.0M
Liabilities
$104.4M
Debt to equity
0.12
IMVT's short-term assets ($948.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMVT's short-term assets ($948.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMVT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IMVT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$95.1M
Investing
-$8.0k
Financing
$3.6M
IMVT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMVT vs Biotech Stocks
Immunovant Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.